Skip to main content

Market Overview

Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition

Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition
  • Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. 
  • Deal terms were not disclosed.
  • Related: Why Did Deutsche Bank Downgrade This Big Pharma Stock?
  • Arctos developed its technology as a potential method for treating inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss, such as age-related macular degeneration.
  • Arctos’ proprietary, light-sensitive optogene is delivered to specific retinal cells using gene therapy, thus turning the targeted cells into replacement photoreceptor-like cells.
  • Arctos was initially incubated by +ND Capital and was later supported by Novartis Venture Fund through a Series A financing round led by +ND Capital.
  • Price Action: NVS stock is up 0.81% at $83.47 during the premarket session on the last check Tuesday.

Related Articles (NVS)

View Comments and Join the Discussion!

Posted-In: Briefs Eye Diseases gene therapyBiotech M&A News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at